302 related articles for article (PubMed ID: 27147616)
1. The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats.
Borner T; Loi L; Pietra C; Giuliano C; Lutz TA; Riediger T
Am J Physiol Regul Integr Comp Physiol; 2016 Jul; 311(1):R89-96. PubMed ID: 27147616
[TBL] [Abstract][Full Text] [Related]
2. Oral Treatment with the Ghrelin Receptor Agonist HM01 Attenuates Cachexia in Mice Bearing Colon-26 (C26) Tumors.
Villars FO; Pietra C; Giuliano C; Lutz TA; Riediger T
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28475119
[TBL] [Abstract][Full Text] [Related]
3. Anorexia-cachexia syndrome in hepatoma tumour-bearing rats requires the area postrema but not vagal afferents and is paralleled by increased MIC-1/GDF15.
Borner T; Arnold M; Ruud J; Breit SN; Langhans W; Lutz TA; Blomqvist A; Riediger T
J Cachexia Sarcopenia Muscle; 2017 Jun; 8(3):417-427. PubMed ID: 28025863
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival.
Fujitsuka N; Asakawa A; Uezono Y; Minami K; Yamaguchi T; Niijima A; Yada T; Maejima Y; Sedbazar U; Sakai T; Hattori T; Kase Y; Inui A
Transl Psychiatry; 2011 Jul; 1(7):e23. PubMed ID: 22832525
[TBL] [Abstract][Full Text] [Related]
5. Z-505, an Oral Ghrelin Receptor Agonist, Attenuates Anorexia After Total Gastrectomy in Rats.
Shiomi Y; Yoshimura M; Hori Y; Ohira Y; Nagahama K; Ozaki T; Takei M; Tanaka T; Uno T
J Surg Res; 2020 Feb; 246():527-534. PubMed ID: 31668932
[TBL] [Abstract][Full Text] [Related]
6. Brainstem GLP-1 signalling contributes to cancer anorexia-cachexia syndrome in the rat.
Borner T; Liberini CG; Lutz TA; Riediger T
Neuropharmacology; 2018 Mar; 131():282-290. PubMed ID: 29247677
[TBL] [Abstract][Full Text] [Related]
7. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.
Zhang H; Garcia JM
Expert Opin Pharmacother; 2015 Jun; 16(8):1245-53. PubMed ID: 25945893
[TBL] [Abstract][Full Text] [Related]
8. Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia.
Wang W; Andersson M; Iresjö BM; Lönnroth C; Lundholm K
Int J Oncol; 2006 Jun; 28(6):1393-400. PubMed ID: 16685441
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.
Esposito A; Criscitiello C; Gelao L; Pravettoni G; Locatelli M; Minchella I; Di Leo M; Liuzzi R; Milani A; Massaro M; Curigliano G
Cancer Treat Rev; 2015 Nov; 41(9):793-7. PubMed ID: 26386985
[TBL] [Abstract][Full Text] [Related]
10. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia.
DeBoer MD; Zhu XX; Levasseur P; Meguid MM; Suzuki S; Inui A; Taylor JE; Halem HA; Dong JZ; Datta R; Culler MD; Marks DL
Endocrinology; 2007 Jun; 148(6):3004-12. PubMed ID: 17347304
[TBL] [Abstract][Full Text] [Related]
11. Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice.
Yoshimura M; Shiomi Y; Ohira Y; Takei M; Tanaka T
Eur J Pharmacol; 2017 Sep; 811():30-37. PubMed ID: 28529141
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats.
Strassburg S; Anker SD; Castaneda TR; Burget L; Perez-Tilve D; Pfluger PT; Nogueiras R; Halem H; Dong JZ; Culler MD; Datta R; Tschöp MH
Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E78-84. PubMed ID: 18460598
[TBL] [Abstract][Full Text] [Related]
13. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.
Graf SA; Garcia JM
Drug Des Devel Ther; 2017; 11():2325-2331. PubMed ID: 28848326
[TBL] [Abstract][Full Text] [Related]
14. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile.
Deboer MD; Zhu X; Levasseur PR; Inui A; Hu Z; Han G; Mitch WE; Taylor JE; Halem HA; Dong JZ; Datta R; Culler MD; Marks DL
Endocrinology; 2008 Feb; 149(2):827-35. PubMed ID: 18039782
[TBL] [Abstract][Full Text] [Related]
15. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model.
Northrup R; Kuroda K; Duus EM; Barnes SR; Cheatham L; Wiley T; Pietra C
Support Care Cancer; 2013 Sep; 21(9):2409-15. PubMed ID: 23579947
[TBL] [Abstract][Full Text] [Related]
16. Multiple Beneficial Effects of Ghrelin Agonist, HM01 on Homeostasis Alterations in 6-Hydroxydopamine Model of Parkinson's Disease in Male Rats.
Minalyan A; Gabrielyan L; Pietra C; Taché Y; Wang L
Front Integr Neurosci; 2019; 13():13. PubMed ID: 31031602
[No Abstract] [Full Text] [Related]
17. Lipopolysaccharide inhibits ghrelin-excited neurons of the arcuate nucleus and reduces food intake via central nitric oxide signaling.
Borner T; Pinkernell S; Lutz TA; Riediger T
Brain Behav Immun; 2012 Aug; 26(6):867-79. PubMed ID: 22465682
[TBL] [Abstract][Full Text] [Related]
18. JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia.
Bresciani E; Rizzi L; Molteni L; Ravelli M; Liantonio A; Ben Haj Salah K; Fehrentz JA; Martinez J; Omeljaniuk RJ; Biagini G; Locatelli V; Torsello A
Endocrine; 2017 Oct; 58(1):106-114. PubMed ID: 27896546
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment.
Ali S; Chen JA; Garcia JM
Curr Opin Support Palliat Care; 2013 Dec; 7(4):368-75. PubMed ID: 24145681
[TBL] [Abstract][Full Text] [Related]
20. Ghrelin receptor inverse agonists as a novel therapeutic approach against obesity-related metabolic disease.
Abegg K; Bernasconi L; Hutter M; Whiting L; Pietra C; Giuliano C; Lutz TA; Riediger T
Diabetes Obes Metab; 2017 Dec; 19(12):1740-1750. PubMed ID: 28544245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
